NatalieSinclairMD

Physician

Dr. Sinclair is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer Start of enrollment: 2021 Jan 11
Recruiting
Phase 2
Roles: Principal Investigator, Contact
MARGetuximab Or Trastuzumab (MARGOT) Start of enrollment: 2020 Jul 13
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
ATEMPT 2.0: Adjuvant T-DM1 vs TH Start of enrollment: 2021 Jun 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

PubMed

Dana-Farber Patient with Breast Cancer Hosts New 'Chemo Coffee Talk' Podcast from Infusion ChairJune 21st, 2024